OpGen (OPGN) Stock Price, News & Analysis

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OPGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OPGN, but not buy additional shares or sell existing shares.
View OPGN analyst ratings or view top-rated stocks.

OpGen's stock was trading at $0.42 at the start of the year. Since then, OPGN shares have increased by 42.9% and is now trading at $0.60.
View the best growth stocks for 2024 here.

OpGen saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,230,000 shares, an increase of 10,621.2% from the March 15th total of 20,800 shares. Based on an average daily volume of 1,670,000 shares, the days-to-cover ratio is presently 1.3 days. Currently, 22.4% of the company's stock are short sold.
View OpGen's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our OPGN earnings forecast.

OpGen, Inc. (NASDAQ:OPGN) issued its earnings results on Thursday, August, 10th. The medical research company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.71) by $0.22. The medical research company had revenue of $0.74 million for the quarter, compared to analyst estimates of $0.90 million. OpGen had a negative net margin of 852.18% and a negative trailing twelve-month return on equity of 316.30%. During the same period last year, the company posted ($2.60) earnings per share.

OpGen's stock reverse split on the morning of Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other OpGen investors own include Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Energy Transfer (ET), Vaxart (VXRT), VBI Vaccines (VBIV), Nabriva Therapeutics (NBRV), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), Pfizer (PFE) and Inovio Pharmaceuticals (INO).

OpGen (OPGN) raised $17 million in an initial public offering on Tuesday, May 5th 2015. The company issued 2,900,000 shares at a price of $5.50-$6.50 per share. Maxim Group served as the underwriter for the IPO and National Securities was co-manager.

Shares of OPGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.